A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of GW685698X [fluticasone furoate; GlaxoSmithKline] aqueous nasal spray 100mcg for 6 weeks in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (PAR)
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Perennial allergic rhinitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 14 Mar 2008 Results reported at AAAAI 2008
- 06 Nov 2007 Status changed from in progress to completed.
- 27 Oct 2006 Status change